Table 3 Adverse events in both groups during therapy
Sitagliptin (n = 85) | Empagliflozin (n = 85) | |
|---|---|---|
One or more adverse effects | 7 (8.2%) | 10 (11.8%) |
One or more adverse effects leading to discontinuation | 0 (0%) | 5 (5.9%) |
Nasopharyngitis | 5 (5.9%) | 3 (3.5%) |
Headache | 1 (1.2%) | 2 (2.4%) |
UTI | 2 (2.4%) | 3 (3.5%) |
Hypoglycemia | 0 (0%) | 1 (1.2%) |
Genital infection | 0 (0%) | 2 (2.4%) |
Hypersensitivity reactions | 2 (2.4%) | 0 (0%) |
Pancreatitis | 2 (2.4%) | 0 (0%) |
Hypotension | 0 (0%) | 1 (1.2%) |
Dehydration | 0 (0%) | 0 (0%) |
Diabetic ketoacidosis | 0 (0%) | 0 (0%) |
GIT upset | 3 (3.5%) | 2 (2.4%) |
Death | 0 (0%) | 0 (0%) |